Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aadi Bioscience, Inc. - Common Stock (NQ: AADI )

3.020 +0.020 (+0.67%)
Streaming Delayed Price Updated: 10:30 AM EST, Dec 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aadi Bioscience, Inc. - Common Stock

< Previous 1 2 Next >
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 59 companies set new 52-week lows. 
Via Benzinga
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  Wednesday's session saw 43 companies set new 52-week lows. 
Via Benzinga
Recap: Aadi Bioscience Q1 Earnings
Via Benzinga
Earnings Preview For Aadi Bioscience
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 36 companies set new 52-week lows. 
Via Benzinga
5 Value Stocks In The Healthcare Sector
Via Benzinga
Aadi Bioscience: Q2 Earnings Insights
  Aadi Bioscience (NASDAQ:AADI) reported its Q2 earnings results on Wednesday, August 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Aadi Bioscience: Q1 Earnings Insights
Aadi Bioscience (NASDAQ:AADI) reported its Q1 earnings results on Thursday, May 12, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Aadi Bioscience beat estimated... 
Via Benzinga
HC Wainwright & Co. Maintains Buy Rating for Aadi Bioscience, Lowers Price Target To $48
HC Wainwright & Co. has decided to maintain its Buy rating of Aadi Bioscience (NASDAQ:AADI) and lower its price target from $49.00 to $48.00. Shares of Aadi Bioscience are trading down 4.87% over the... 
Via Benzinga
Aadi Bioscience: Q4 Earnings Insights
Aadi Bioscience (NASDAQ:AADI) reported its Q4 earnings results on Thursday, March 17, 2022 at 07:00 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
Canadian Biotech Disruptor Lexston Life Sciences is unlocking the God Molecule (LEXTF, ICPT, AKBA, QURE, BNTX, SAVA)
Via AB Newswire
Topics Bonds Stocks
Exposures Debt Markets US Equities
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Omeros (NASDAQ:OMER) stock increased by 15.68% to $7.89 during Thursday's pre-market session. The market value of their outstanding shares is at $493.4 million... 
Via Benzinga
The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, & More
Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news about a new COVID-19 variant helped mitigate the losses notched earlier in the holiday-shortened week. 
Via Talk Markets
Exposures COVID-19 Product Safety
The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, BeyondSpring, CTI Biopharma And Merck Take The Spotlight In A Light Calendar Week
Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news about a new COVID-19 variant, named Omicron, helped mitigate the losses... 
Via Benzinga
Exposures COVID-19 Product Safety
What 4 Analyst Ratings Have To Say About Aadi Bioscience
Analysts have provided the following ratings for Aadi Bioscience (NASDAQ:AADI 
Via Benzinga
Aadi Bioscience Stock Pops On First-Ever FDA Approval In Rare Cancer
Aadi Bioscience won FDA approval for a drug to treat rare tumors. 
Via Investor's Business Daily
Exposures Product Safety
The Daily Biotech Pulse: Arrowhead Out-Licenses NASH Drug, Tonix Touts COVID-19 Treatment Data, Aadi Jumps On FDA Nod For Rare Tumor Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Synlogic Presents Positive Phase 2 Data For Synthetic Biologic Treatment In... 
Via Benzinga
Exposures COVID-19 Product Safety
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Pasithea Therapeutics (NASDAQ:KTTA) stock increased by 157.46% to $5.69 during Tuesday's pre-market session. The company's market cap stands at $75.1... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning, investors! We're getting right back to the grind today with a dive into the biggest pre-market stock movers for Tuesday. 
Via InvestorPlace
Exposures COVID-19 Product Safety
Aadi Bioscience Shares Rally On FDA Approval For Its First Product For Rare Form Cancer
The FDA has approved Aadi Bioscience Inc's (NASDAQ: AADI) Fyarro (sirolimus protein-bound particles for injectable suspension) (albumin-bound) for perivascular... 
Via Benzinga
Exposures Product Safety
The Week Ahead In Biotech (Nov. 21-Nov. 27): FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reporting... 
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the... 
Via Benzinga
Exposures Product Safety
Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates
The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes. PDUFA dates are key binary events for biotech stocks that can move the needle in a... 
Via Benzinga
76 Biggest Movers From Yesterday
Gainers Expensify, Inc. (NASDAQ: EXFY) jumped 52.1% to settle at $41.06 on Wednesday after the company priced its IPO at $27 per share. RenovoRx, Inc. (NASDAQ: RNXT) shares... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares... 
Via Benzinga
Exposures COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For October 1, 2021
Upgrades Northland Capital Markets upgraded the previous rating for Five9 Inc (NASDAQ: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 8, 2021
Upgrades For SilverBow Resources Inc (NYSE: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2021
Upgrades Northcoast Research upgraded the previous rating for Casey's General Stores Inc ... 
Via Benzinga
60 Biggest Movers From Friday
Gainers Vinco Ventures, Inc. (NASDAQ: BBIG) shares rose 80.9% to close at $5.30 on Friday. The company recently reported a Q2 loss of $5.13 per share. Navios Maritime Acquisition... 
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.